Optimizing weight loss with artificial intelligence: A randomized controlled trial of dietary-supplement prescriptions in adults with overweight and obesity.

Plain-language guide to PMID 40562096 (2025): parallel-group randomized controlled trial of Copper (Supplement) in 60 individuals, fat loss, obesity & body recomposition.

Key Facts

PMID: 40562096
Journal: Clinical nutrition ESPEN
Year: 2025
Study type: Randomized Controlled Trial
Authors: Pokushalov E et al. (11 authors)
DOI: 10.1016/j.clnesp.2025.06.035
Registered trial: NCT06458296

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in the context of fat loss, obesity & body recomposition in this randomized controlled trial publication.

Who Took Part

The abstract describes 60 individuals taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

This randomized, parallel-group pilot study enrolled 60 individuals aged 40-60 years with a body-mass index (BMI) ≥ 25 kg m-2.

How the Study Was Run

In design terms this was a randomized, parallel-group and pilot study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the individuals stayed in one arm throughout.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Secondary endpoints included changes in BMI, fat mass, visceral-fat rating, systolic and diastolic blood pressure, lipid profiles, fasting plasma glucose, hsCRP levels, and postprandial appetite ratings.

Adverse events were monitored throughout the study.

What Was Measured

The subject headings attached to it are Weight Loss, Obesity, Overweight, Artificial Intelligence, Pilot Projects, Body Mass Index and Dietary Supplements.

Author keywords: AI-guided, Appetite suppression, Metabolic health and Personalized medicine.

What This Means in Plain Language

The paper is a randomized, parallel-group and pilot study of Copper (Supplement) in 60 individuals in people with fat loss, obesity & body recomposition.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Clinical nutrition ESPEN), a journal based in England.

More context: the Copper (Supplement) compound page, Fat loss, obesity & body recomposition research.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.